Recurrent Miscarriage Clinical Trial
Official title:
Walking and Dietary Modification for Women With Consecutive Early Miscarriages: a Randomized Study
This study is part of a big one aiming to evaluate how lifestyle interventions during
pregnancy affect obstetric results, neonatal metabolism and the intelligence of the
offspring (study not yet completed). Data regarding obstetric and neonatal results were
entered in NCT01409382, but we decided to split results in two for the sake of clarity.
A cohort of women with early pregnancy losses without antiphospholipid antibodies was
selected for two reasons. One is that these women follow strictly the recommendadtions. The
second is that no medication has been shown to increase the rate of take-home babies in
women with early miscarriages who test negative for antiphospholipid antibodies. We decided
to focus on the fibrinolytic system because trophoblast migration and placental
vasculogenesis and angiogenesis depend on plasmin-dependent extracellular matrix remodeling.
Plasminogen activator inhibitor (PAI)-1 inhibits the generation of plasmin. Since both
glucose and insulin increase PAI-1 synthesis, hyperglycemia itself, or by stimulating
insulin production, reduces plasmin generation, which may impair placentation.
Abnormalities in glucose metabolism may be also deleterious to embryos by causing epigenetic
changes. Chromosomal abnormalities are considered an important cause of early pregnancy
losses.
Several lines of evidence lend support to the hypothesis that carbohydrate metabolism
abnormalities contribute to the pathogenesis of recurrent early pregnancy losses. One is
that of the pregnancies of the women with polycystic ovary syndrome, around 30 and 50% end
with first-trimester miscarriages. Hyperinsulinemia is a prevalent feature of the syndrome,
and interventions proven effective in reducing insulin levels, such as metformin, have been
shown to reduce the rate of early miscarriages. The other is that patients with body mass
index of ≥25 kg/m2 have significantly higher odds of early miscarriage, regardless of the
method of conception.
The investigator's hypothesis was that a balanced diet combined to regular exercise, by
improving glucose homeostasis, would increase the take-home baby rate in women with
consecutive early miscarriages. Moderate exercises are usually well tolerated not only by
the mother, but also by the fetus, as indicated by tests of fetal well-being, including
umbilical artery systolic to diastolic ratio.
Women aged 18 to 40 years trying to conceive spontaneously were eligible if they had two or
more consecutive pregnancy losses in the first trimester, documented by pathology or
ultrasound-confirmed gestational sac.
All participants underwent ultrasound examination before inclusion in the study. Exclusion
criteria were any of the following: anatomic anomalies that may increase the risk of
pregnancy losses, not amenable to surgical correction during pregnancy, such as uterine
septum; antiphospholipid antibodies; prior second- or third-trimester losses; current
multiple gestation; disabilities such as hemiplegia or paraplegia; renal or liver failure;
conditions requiring a priori anticoagulation.
Participants were enrolled by staff at the participating center. Randomization to the
intervention protocol Walking and Diet (W&D) or to a control group was performed before
pregnancy occurred by a statistician using a computer-generated random-number table. This
was not a double blind study, but care was taken to ensure that appointments of the patients
assigned to the intervention protocol did not coincide with those of controls.
The intervention was standardized by training of research staff. Women assigned to W&D were
instructed to walk at a moderate pace (4 km/h) for at least 40 minutes, seven days a week.
Besides, those who remained seated most of the day were advised to walk 25 to 30 minutes
twice a day, avoiding hence more than 12 hours of physical inactivity. Walking could be
replaced by stationary bicycle rides or swimming when convenient, which often occurred near
term and when the mother was obese. Strenuous exercises were discouraged.
Patients assigned to protocol W&D were also informed of the importance of a balanced diet
and recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber). Sucralose
could be used as a sweetener. As a strategy to promote satiety and reduce carbohydrate
intake, W&D participants were also advised to eat at least two daily servings of
protein-rich food. The intervention began when participants wished to conceive, continuing
until delivery. Careful instructions about walking speed and diet were given to participants
assigned to W&D at enrolment and at each consultation. During exercise, neither fetal nor
maternal cardiac rate were assessed.
Non-adherence to the intervention protocol was suspected when non-obese participants
assigned to W&D gained > 1 kg in 4 weeks until the 28th week of gestation, > 1.5 kg from the
28th to the 32nd week, and > 2 kg in 4 weeks thereafter, in the absence of edema. The
threshold was lower for obese participants: > 700 g in 4 weeks until the 28th week of
gestation, > 1 kg from the 28th to the 32nd week, and > 1.5 kg in 4 weeks thereafter21.
Excessive weight gain aroused the suspicion of protocol violation because high carbohydrate
consumption, especially when combined with physical inactivity stimulates the pancreas to
overproduce insulin, a hormone that promotes fat storage. To enhance adherence to the
protocol, W&D participants who gained excessive weight were recommended to increase the
frequency, duration and intensity of the physical activity and to increase the protein
intake. Participants of the W&D group who had a successful pregnancy volunteered to
encourage mothers assigned to the intervention protocol, especially those who gained
excessive weight.
At enrollment and during first-trimester consultations, W&D participants were explained that
antiemetics such as ondansetron should be taken before nausea became severe, in order to
help them tolerate balanced meals.
No recommendations regarding diet or physical activity were given to controls. Antiemetics
such as ondansetron were given to controls who complained of hyperemesis.
All participants were given folic acid tablets 5 mg daily until 14 weeks of gestation, as
prevention of neural tube defects. In both groups, participants reporting abdominal pain,
cramps, and vaginal bleeding during the first-trimester were medicated with vaginal
progesterone. Subcutaneous heparin was given to all participants whose pregnancies were
complicated with nephrotic range proteinuria or any evidence of placental insufficiency.
Antihypertensive medications included methyldopa, amlodipine and hydralazine. No patient
received aspirin or metformin in this study.
Appointments were scheduled according to the routine. Maternal weight and blood pressure
were assessed at every appointment and all mothers were screened for gestational diabetes
according to the American Diabetes Association recommendations.
Obstetric and neonatal outcomes were obtained from the hospital records. Neonates were
classified as small, appropriate or large for gestational age according to Olsen et al.
growth curves.
Written informed consent was obtained from each participant after a full explanation of the
study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01419392 -
Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages
|
Phase 4 | |
Completed |
NCT00193674 -
Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage
|
Phase 3 | |
Completed |
NCT06001060 -
Distinct Alterations in Gut Microbiota Composition Among Women of Reproductive Age With Elevated Homocysteine Levels.
|
||
Recruiting |
NCT05034250 -
Iron Status in Female Infertility and Recurrent Miscarriage
|
||
Completed |
NCT02681627 -
Sim (Scratch in Miscarriage) Study
|
N/A | |
Recruiting |
NCT02303171 -
Use of Warfarin After the First Trimester in Pregnant Women With APS
|
Phase 4 | |
Completed |
NCT02305420 -
EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage
|
Phase 4 | |
Recruiting |
NCT05824897 -
The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome
|
||
Not yet recruiting |
NCT03132779 -
Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion
|
Phase 1 | |
Completed |
NCT02184741 -
A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage
|
Phase 3 | |
Active, not recruiting |
NCT02156063 -
A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)
|
Phase 2 | |
Recruiting |
NCT03902912 -
Effect of Prednisolone Treatment on Uterine Natural Killer Cells
|
Phase 3 | |
Not yet recruiting |
NCT03209063 -
The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage
|
||
Completed |
NCT03970954 -
Low-dose Interleukin-2 in Women With Unexplained Miscarriages
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06249230 -
The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk
|
||
Recruiting |
NCT05725512 -
Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
|
Phase 4 | |
Recruiting |
NCT05267678 -
Nutritional Deficiency and Recurrent Miscarriage
|
||
Completed |
NCT02504281 -
Study on the Association Between SXCI and RM and the Possible Genetic Mechanism
|
||
Completed |
NCT02694367 -
Expression of EPK in Recurrent Miscarriage
|
N/A | |
Completed |
NCT01608347 -
Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies
|
Phase 4 |